These are our frequently asked questions. If you have a question that’s not answered here, please contact the team.

  • What is BioLife?

    A private sidechain of ACChain, BioLife is an on-chain asset digitization and private records handler for patients, investors and owners of global biomedical resources.
    Employing distributed ledger technology (DLT), BioLife offers a traceable, secure, convenient, and confidential channel for activity within the bioscience resources community worldwide.

  • What is BIOT?

    The native currency and exclusive medium of value exchange inside BioLife, BIOT is structured in a way that supports the entire BioLife digital ecosystem. In the context of token adoption, BIOT supports development within BioLife in many ways, including:

    • as a widely adopted medium of value exchange throughout the global bioscience and medical tourism marketplace
    • as a governance tool
    • as a reward for proposing and/or implementing new improvements to the platform
    • in the creation of a protocol layer for third-party applications
    • as a reward for valuable knowledge sharing
    • as a means of monetization for third-part vendors
    • as an access API to the BioLife platform
    • as a reward for securing the platform

    This will increase liquidity of the whole BioLife ecosystem, steepening the velocity of BIOT as its native and exclusive currency, possibly resulting in higher appreciation of BIOT as adoption expands and the platform becomes popular.

  • What is DLT?

    Distributed Ledger Technology (DLT) is a digital system for recording transactions of assets. Unlike traditional databases, distributed ledgers have no central data store or administrative functionality. Transactions and their details are recorded in multiple places within a network of computers, at the same time.

  • What is a smart contract?

    A smart contract, also known as a cryptocontract, is a computer program that directly controls the transfer of digital assets or currencies between parties under certain conditions. The rules and penalties related to an agreement are defined within the smart contract in the same way they are in a traditional agreement, only with a smart contract these obligations are also automatically enforced.

    Smart contracts were first proposed in 1994 by Nick Szabo, an American computer scientist who invented a virtual currency called “Bit Gold” in 1998 (10 years before Bitcoin was invented).

  • How does BioLife function?

    BioLife is built on the private chain group based on AAChain bottom layer technology.

    Pharmaceutical companies, biomedical institutions and other life science health service providers, along with patients of these specialised resources, are invited to contribute to BioLife’s application scenarios, including the digitization of physical assets and creation of electronic health records (EHR).

    The BioLife service platform provides digital access for owners of biomedical resources. Assets become biomedical digital assets, and respective genesis blocks are created for launch online and circulation.

  • What is Bioscience?

    Bioscience develops biological solutions to sustain, restore and improve quality of life for humans, plants and animals in our world.

  • What is the Purpose of BioLife?

    The value of global bioscience resources is immeasurable. BioLife will increase the visible value of bioscience resources worldwide.

  • What is ACChain?

    ACChain is a public chain anchored with physical assets that provides simple asset digitization and decentralized circulation. BioLife is a private chain linked to ACChain.

  • Who is Swiss Vitality Cells Laboratory Limited?

    Swiss Vitality Cells Laboratory Limited is the initiator of BioLife chain. The company has five major roles within the life sciences chain including financial accounting, technology, production and operation, marketing and human resource management. It acts within these in an integrated manner, and is also in charge of planning, executing and controlling the entire process of the company’s operation and management.

    The BioLife ecosystem consists of healthcare producers, service providers and scientific research institutions. With the development of BioLife, there will be a growing number of health assets joining the ecosystem and providing open, transparent and traceable health assets and redemption.

    Swiss Vitality Cells Laboratory Limited is also the operating company of BioLife and in charge of the development, maintenance and management of the BioLife service platform and ecosystem. This company will be responsible for and will be supervised by the BioLife community as the operational management agency of BioLife.

  • Who is Swiss Serolab®?

    Swiss Serolab® of Leukerbad Wellness Management Group LTD. was founded in 1958. Established by French M.D. Jean Thomas, the company has the earliest polyclonal antibody lab in Europe with the most complete biopharmaceutical technology. It has received the GMP Certification of Management Qualification for International Pharmaceutical Production – the production and distribution license of the Swiss Agency for Therapeutic Products or Federal Office of Public Health.

    For 60 years, Swiss Serolab® of Leukerbad Wellness Management Group LTD. has been dedicated to research and seeking better treatment solutions for functional illness in order to provide complementary therapies to accompany traditional ones. Leukerbad’s intellectual property portfolio includes over 1,000 bioscience patents, covering areas from anti-aging to major illness precaution. Known for its outstanding healing effect and security, Leukerbad is praised by industry experts and is highly popular among celebrities and politicians throughout the world.

  • What is the BioLife Service Platform?

    The BioLife Service Platform is a global high-end biomedical resources platform for patients, investors, and owners of biomedical resources. It aims to provide a safe, private, reliable, efficient and economical foundation for a thriving biosciences community. Products, services, personal data and assets relevant to life sciences health care will be digitized and traded by BioLife Token (BIOT) holders who may invest in R&D and secure their assets through smart contracts on the BioLife Service Platform.


Find out more about the BioLife Token Sale